#Noteworthy bold license for free#
Malaysian media reported that patients will receive treatment for free that the government buys for the price of RM1,000 (About US$ 240,-) per patient. In March, Malaysia’s hepatitis C treatment implementation took off following the decision to issue a compulsory licence of sofosbuvir patents in September 2017, which made it possible to procure and supply generic antiviral medicines. Check out the month of December in this post for more information! The data that formed the basis for the paper is maintained by Medicines Law & Policy. The paper shows that the use of TRIPS Flexibilities was more frequent than is commonly assumed. The Bulletin of the World Health Organization published a new paper documenting the use of TRIPS flexibilities in the procurement of medicines from 2001-2016.
You can monitor compulsory licensing requests using our TRIPS Flexibilities database, available here. For the time being, the compulsory licensing procedure is on ice. Novartis had earlier threatened Colombia with an investor state dispute under the Swiss-Colombian bilateral investment treaty. Mavyret is priced in the US at US$ 26,400.Īlso in February, the Swiss NGO Public Eye obtained a copy of a letter by Novartis CEO Joseph Jiminez written to the President of Colombia to persuade Colombian authorities to refrain from using compulsory licensing to assure access to lower-priced versions of the cancer drug Glivec (imatinib). In the US, Harvoni is priced at US$ 96,000 for a 12 week course, some have negotiated a price of US$ 20,000. Starting treatment earlier can prevent such serious and life threatening complications. In their letter, they point out that high prices of antiviral medicines such as Gilead’s Harvoni (sofosbuvir/ledipasvir) and Abbvie’s Mavyret (glecaprevir/pibrentasvir) led to restrictions of reimbursement of treatment cost to only patients with advanced stages of the disease, such as liver damage.
On 15 February, 18 members of the US House of Representatives called for compulsory licensing of patents for the treatment of hepatitis C. The Drugs for Neglected Diseases Initiative together with Sanofi announced the submission to the European Medicines Agency of the request for the review of their medicine fexinidazole, the first ever oral treatment for sleeping sickness, a disease endemic in Africa. In Chile the cost of sofosbuvir, one of the essential medicines to treat hepatitis C, was US$36,000 per patient per year. The adoption of resolution Number 1014 was unanimous. The request was made by patients, their advocates and elected officials in March 2017. The Chilean parliament started 2018, on 3 January, with the adoption of a resolution calling on the President to advance the compulsory licensing request for medicines needed to treat hepatitis C. We are reaching the end of 2018: Time for our end-of-the-year roundup of some significant developments in medicines law and policy.
0 kommentar(er)
